Discover 775 paid clinical trials in Washington, D.C.. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 775
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
for
Non-obstructive Hypertrophic Cardiomyopathy
Location: Washington D.C. DC, Baltimore MD, Richmond VA,
Sponsor: Imbria Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT07023614
Phase 2, Recruiting
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
for
Growth Hormone Deficiency (GHD)
Location: Washington D.C. DC, Charlottesville VA,
Sponsor: Lumos Pharma
Sex: All
Age: 3 - 11
Code: NCT06948214
Phase 3, Recruiting
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
for
Graves Disease
Location: Washington D.C. DC, Midlothian VA, Philadelphia PA,
Sponsor: Biohaven Therapeutics Ltd.
Sex: All
Age: 18 - 70
Code: NCT07661056
Phase 3, Recruiting
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
for
Generalized Myasthenia Gravis
Location: Washington D.C. DC, Charlottesville VA, New York NY,
Sponsor: Immunovant Sciences GmbH
Sex: All
Age: 18 - 70+
Code: NCT07039916
Phase 3, Recruiting
Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387
Post-Procedural Manual Manipulation for Infant Ankyloglossia
for
Ankyloglossia, Breastfeeding Support
Location: Washington DC
Sponsor: Georgetown University
Sex: All
Age: 0
Code: NCT06830148
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
for
Non-small Cell Lung Cancer
Location: Washington D.C. DC, Fairfax VA, Frederick MD,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT06712316
Phase 2, Phase 3, Recruiting
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
for
Thymoma, Thymic Carcinoma
Location: Washington D.C. DC, Hackensack NJ, Chicago IL,
Sponsor: Georgetown University
Sex: All
Age: 18+
Code: NCT06248515
Phase 2, Recruiting
Phase IB/II of CPX-351 for Relapse Prevention in AML
for
Acute Myeloid Leukemia (AML) in Remission
Location: Washington D.C. DC, Philadelphia PA, Hackensack NJ
Sponsor: Georgetown University
Sex: All
Age: 18+
Code: NCT04990102
Phase 1, Phase 2, Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
for
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis,
Location: Washington D.C. DC, Bethesda MD, Baltimore MD,
Sponsor: Kartos Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06479135
Phase 3, Recruiting
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
for
Solid Tumor, MET Alteration
Location: Washington D.C. DC, Canton OH, Nashville TN
Sponsor: Pierre Fabre Medicament
Sex: All
Age: 18+
Code: NCT06669117
Phase 1, Phase 2, Recruiting
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
for
Solid Tumors, GI Cancer
Location: Washington DC, Baltimore MD, Durham NC, Boston MA,
Sponsor: Curegenix Inc.
Sex: All
Age: 18+
Code: NCT02675946
Phase 1, Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
for
Colorectal Neoplasms
Location: Washington D.C. DC, Arlington VA, Fairfax VA,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06662786
Phase 3, Recruiting
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
for
Non-small Cell Lung Cancer
Location: Washington D.C. DC, Fairfax VA, Baltimore MD,
Sponsor: Teligene US
Sex: All
Age: 18+
Code: NCT05168566
Phase 2, Recruiting
Addressing Genomic Disparities in Cancer Survivors
for
Hereditary Cancer, Genetic Testing
Location: Washington D.C. DC, New Brunswick NJ
Sponsor: Rutgers, The State University of New Jersey
Sex: All
Age: 18 - 70+
Code: NCT06073626
Recruiting
MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer